Abstract Library

#4592 Uncovering cell-state heterogeneity in large-cell panNEC indicates potentially targetable aberrant brain type neuronal de-differentiation

Introduction: Classification and treatment of high-grade pancreatic neuroendocrine carcinoma (panNEC), particularly those with large-cell morphology, present significant clinical challenges due to considerable inter- and intra-patient tumour heterogeneity.

Conference:

Presenting Author: Debnath O

Authors: Debnath O, Berger H, Detjen K, Kirchner P, Marinoni I,

Keywords: pancreatic neuroendocrine carcinoma, single cell, personalised medicine,

#4413 Efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia (APSIN) – A multi-centre, prospective, randomised, controlled, phase III study

Introduction: Our multi-centre, prospective, open-label, two-arm parallel group, randomised, controlled, phase III study will address the efficacy and safety of adjuvant peptide receptor radionuclide therapy after curative surgery of locoregional limited small intestine neuroendocrine neoplasia.

Conference:

Presenting Author: Eilsberger F

Authors: Eilsberger F, Luster M, Rau J, Avci H, Schade-Brittinger C,

Keywords: adjuvant therapy, neuroendocrine neoplasia, small intestine, peptide receptor radionuclide therapy, PRRT,

#4258 Unanticipated heterogeneity in high-grade large-cell neuroendocrine carcinoma pinpoints cell sub-state specific therapeutic targets

Introduction: High-grade pancreatic neuroendocrine carcinoma (panNEC) pose challenges in terms of classification and treatment. While molecular genetics have made strides in deciphering significant inter-tumor heterogeneity, the extent of intra-tumoral heterogeneity and lineage plasticity remains unexplored.

Conference:

Presenting Author:

Authors: Debnath O, Detjen K, Berger H, Kirchner P, Marinoni I,

Keywords: PanNEC, Single cell RNAseq,

#3189 Real-world outcomes of patients with neuroendocrine liver metastases treated with trans-arterial radioembolization: Results from CIRT, a large European prospective multi-centre observational study

Introduction: Trans-arterial radioembolization (TARE) is a treatment option for patients with liver dominant metastases from neuroendocrine tumors (mNET). The CIRSE Registry for SIR-Spheres Therapy (CIRT) is a European prospective multi-centre observational study conducted by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Helmberger T

Authors: Helmberger T, Schaefer N, Pech M, Pfammatter T, Maleux G,

Keywords: liver metastases, observational study, yttrium-90, trans-arterial radioembolization, registry, therapeutic embolization, SIRT,

#2846 Whole Genome DNA Methylation Profiling Identifies Neuroendocrine Tumor Origin

Introduction: Determining the origin of a neuroendocrine tumor (NET) of unknown primary can be challenging. Liver metastases can originate from any organ in the body, while pulmonary NETs can be metastases but also primary tumors. This especially holds true for Multiple Endocrine Neoplasia Type 1 patients, who often have multiple primary pancreatic and intestinal NETs. It is important to know the origin of the primary tumor since resection or ablation is crucial in case of treatment with curative intent. Furthermore, the site of origin determines prognosis, treatment options and eligibility for clinical trials.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hackeng W, Geisenberger C, de Leng W, Morsink F, Vriens M,

Keywords: Methylation profiling, Neuroendocrine tumor, Machine Learning, Unknown Primary,